Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology.

Imaging of response to oncology treatments, either on clinical protocol or as part of standard practice, is a complicated process that has evolved during the last 10 years due to the improvement of existing imaging technologies and the introduction of newer modalities. Diffusion magnetic resonance imaging is a technique that measures the mobility of water within tissues and, as such, may function as a surrogate marker for both tissue cellularity and response to treatment that occur earlier than usual measures of tumor response. This review highlights the development of this technique and the state of current clinical understanding of its utility.

[1]  M. Bastin,et al.  Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging. , 2007, Magnetic resonance imaging.

[2]  G. Parker,et al.  DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.

[3]  D. Auer,et al.  Diffusion-weighted magnetic resonance imaging of treatment-associated changes in recurrent and residual medulloblastoma: preliminary observations in three children , 2006, Acta radiologica.

[4]  R. J. Seitz,et al.  EFNS guideline on neuroimaging in acute stroke. Report of an EFNS task force , 2006, European journal of neurology.

[5]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[6]  T. Hirai,et al.  Monitoring therapeutic responses of primary bone tumors by diffusion-weighted image: initial results , 2006, European Radiology.

[7]  Mathias Langer,et al.  Osteosarcoma: Preliminary Results of In Vivo Assessment of Tumor Necrosis After Chemotherapy With Diffusion- and Perfusion-Weighted Magnetic Resonance Imaging , 2006, Investigative radiology.

[8]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Sorensen,et al.  Magnetic resonance as a cancer imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  N. Hylton.  Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  W. Weber.  Positron emission tomography as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  F. Miller,et al.  Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. , 2006, Journal of vascular and interventional radiology : JVIR.

[13]  Bradford A Moffat,et al.  Dynamic imaging of emerging resistance during cancer therapy. , 2006, Cancer research.

[14]  N. Tomura,et al.  Diffusion Changes in a Tumor and Peritumoral Tissue After Stereotactic Irradiation for Brain Tumors: Possible Prediction of Treatment Response , 2006, Journal of computer assisted tomography.

[15]  Bradford A Moffat,et al.  The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. , 2006, Neoplasia.

[16]  D. Bluemke,et al.  The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. , 2006, Journal of vascular and interventional radiology : JVIR.

[17]  C. Meyer,et al.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Y. Ni,et al.  Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration. , 2005, Neoplasia.

[19]  M. Jacobs,et al.  Uterine fibroids: diffusion-weighted MR imaging for monitoring therapy with focused ultrasound surgery--preliminary study. , 2005, Radiology.

[20]  Bradford A Moffat,et al.  Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[22]  Dirk Strumberg,et al.  Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  David A Bluemke,et al.  Assessment of Response of Uterine Fibroids and Myometrium to Embolization Using Diffusion-Weighted Echoplanar MR Imaging , 2005, Journal of computer assisted tomography.

[24]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[25]  Bradford A Moffat,et al.  Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker , 2004, Clinical Cancer Research.

[26]  D. Yee,et al.  Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy--a pilot study at 4 T. , 2004, Radiology.

[27]  R. Gillies,et al.  Changes in water mobility measured by diffusion MRI predict response of metastatic breast cancer to chemotherapy. , 2004, Neoplasia.

[28]  Bradford A Moffat,et al.  The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[29]  Jean-François Daisne,et al.  Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. , 2004, Radiology.

[30]  S. Maier,et al.  High-b-value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumor response to therapy in mice. , 2004, Radiology.

[31]  Stephan E Maier,et al.  Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. , 2004, Neoplasia.

[32]  S. Mukherji,et al.  Evaluation of head and neck squamous cell carcinoma after treatment. , 2003, AJNR. American journal of neuroradiology.

[33]  D. Bluemke,et al.  Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. , 2003, AJR. American journal of roentgenology.

[34]  Alexander de Vries,et al.  Preliminary Results on the Influence of Chemoradiation on Apparent Diffusion Coefficients of Primary Rectal Carcinoma Measured by Magnetic Resonance Imaging , 2003, Strahlentherapie und Onkologie.

[35]  Jürgen Griebel,et al.  Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[36]  Stephan E Maier,et al.  Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Jan Wolber,et al.  Diffusion MRI for prediction of response of rectal cancer to chemoradiation , 2002, The Lancet.

[38]  J. Finsterbusch,et al.  Diffusion-weighted MR imaging of metastatic disease of the spine: assessment of response to therapy. , 2002, AJNR. American journal of neuroradiology.

[39]  A. Rieber,et al.  Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy , 2002, European Radiology.

[40]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[41]  P J Drew,et al.  Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[42]  S E Maier,et al.  Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. , 2001, Cancer research.

[43]  J. M. Taylor,et al.  Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. , 2000, Journal of the National Cancer Institute.

[44]  P. Ellen Grant,et al.  Diffusion-weighted MR imaging of the brain. , 2000, Radiology.

[45]  Olav Haraldseth,et al.  Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging , 2000, Magnetic resonance in medicine.

[46]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[48]  R. Gillies,et al.  Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. , 1999, Neoplasia.

[49]  T L Chenevert,et al.  Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  J. Pipe,et al.  Early detection of treatment response by diffusion-weighted 1H-NMR spectroscopy in a murine tumour in vivo. , 1996, British Journal of Cancer.

[51]  P. Picci,et al.  Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  D. Le Bihan,et al.  Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. , 1988, Radiology.

[53]  Tobias Schaeffter,et al.  Magnetic resonance imaging and spectroscopy. , 2008, Handbook of experimental pharmacology.

[54]  Thomas E Yankeelov,et al.  Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. , 2007, Magnetic resonance imaging.

[55]  D. Bluemke,et al.  Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. , 2007, Journal of vascular and interventional radiology : JVIR.

[56]  A. Makris,et al.  Evaluation of good clinical response to neoadjuvant chemotherapy in primary breast cancer using [18F]-fluorodeoxyglucose positron emission tomography. , 2002, European journal of cancer.

[57]  Thomas L Chenevert,et al.  Magnetic Resonance Imaging and Spectroscopy: Application to Experimental Neuro-Oncology. , 1994, Quarterly of magnetic resonance in biology and medicine.